drugset / Trial / NCT05642962
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2026-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pancrelipase | Protein / enzyme biologic | 384 iu/kg | — |
| Subject | Pancrelipase | Protein / enzyme biologic | 1350 iu/kg | — |